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Background: Cardiac disease is the most common cause of morbidity and mortality in the United Kingdom. Even
minor changes in thyroid hormone concentration may impact adversely on the cardiovascular system. Subclinical
hypothyroidism (SCH) after admission for an acute cardiac problem has been associated with an increase in cardiac
mortality and overall death. We have designed protocols for a prospective observational study to assess the association
of thyroid function at the time of acute myocardial infarction (AMI) with cardiovascular outcomes, and a double-blinded
randomised placebo-controlled trial of levothyroxine to evaluate its effect on LV function and vascular health.
Methods/Design: ThyrAMI 1: This will be a prospective longitudinal observational study of patients with AMI that will
be followed for 24 months to study the association between thyroid status at the time of AMI (within 24 hours of
diagnosis) with vascular outcomes.
ThyrAMI 2: This will be a prospective double-blinded randomised placebo-controlled trial of levothyroxine of 12 months
duration in patients with AMI and SCH.
Setting: Patients will be recruited from five hospitals in the North East of England.
Participants: One hundred patients with thyroid function tests within the subclinical hypothyroid range upon admission
with an AMI and no previous history of thyroid disease.
Intervention: Levothyroxine will be administered at a starting dose of 25 mcg once daily, which will be increased at
intervals if needed to maintain a TSH level between 0.4 to 2.5 mU/L, versus a placebo.
Randomisation: Participants will be randomized with a computerised randomisation algorithm, stratified by type of MI
(NSTEMI versus STEMI), in a 1:1 ratio to levothyroxine therapy or placebo (as container or bottle numbers), starting within
21 (+/− 7) days of AMI.
Blinding: Assignment to either the LT4 or placebo arm will be double-blinded.
Outcomes: The outcome will be the effect of levothyroxine on ventricular function, endothelial function and blood
coagulability and rheology.
Discussion: There is evidence to suggest that treatment of SCH can improve cardiovascular parameters. Therefore,
ThyrAMI 1 and ThyrAMI 2 will be the first trials investigating SCH in AMI to give a better insight into whether thyroid
hormone levels are a key target for improving cardiovascular outcomes.
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Figure 1 Flow chart representing ThyrAMI 1 observational study
and identification of potential cohort for the interventional trial
ThyrAMI 2.
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Cardiac disease is the most common cause of morbidity
and mortality in the United Kingdom, costing £29 billion
[1]. Much research on cardiovascular disease has focused
on men, as these diseases occur at younger ages and are
more severe in males, and risk factors for cardiovascular
disease in women are relatively understudied. Thyroid
disease is predominantly a disease of women and is in-
creasingly being recognised as an adverse cardiac risk
factor. Levothyroxine is cheap (costs 5 pence/day), safe
and commonly used generic drug (prescribed to 3% of
the UK population). The appropriate use of levothyrox-
ine in SCH patients with and without heart disease has
the potential to optimise management of hypothyroidism
to minimise vascular risk and to improve outcomes of
AMI. The myocardium and vascular endothelial tissues
have receptors for thyroid hormones and are sensitive to
changes in circulating thyroid hormone concentration [2].
Even minor changes in thyroid hormone concentration
may impact adversely on the cardiovascular system. Im-
portantly, both mild hypothyroidism (SCH) and hyperthy-
roidism have been associated with a 20 to 80% increase in
vascular morbidity and mortality risk [3-7]. This has huge
population significance as a vascular risk factor, since at
least 10% of older women have SCH, but this is under-
recognised, owing possibly to a lack of commercial ex-
ploitability. Small intervention trials of levothyroxine in
SCH have shown improvement in left ventricular func-
tion, vascular endothelial function and atherogenic lipid
particles [8]. SCH after an acute cardiac problem has been
associated with an up to 3.6-fold increase in cardiac
mortality and a 2.3-fold increase in overall death [9,10].
Following experimental coronary artery ligation in an
animal model of AMI, heart failure is associated with re-
duced thyroid hormone receptor expression in the myo-
cardium, leading to tissue hypothyroidism [11]. Moreover,
thyroid hormone administration improves cardiac con-
tractility, left ventricular (LV) function, and augments
myocardial remodelling [12]. In addition, thyroid hor-
mone regulates angiogenesis, cardio-protection, cardiac
metabolism, and myocyte regeneration at a molecular
level, changes that can reverse left ventricular remodelling
by favourably improving myocyte shape and geometry of
LV cavity, thus improving recovery from AMI [13].
Analysis of more than 3,000 participants aged 65 years
or older without heart failure at baseline, who were
followed up for 12 years in the Cardiovascular Health
Study, showed that SCH participants who were treated
with levothyroxine had a 72% reduction in heart failure
events [14]. Several other studies have shown similar re-
sults [15-17]. Thus, even mild hypothyroidism following
AMI could be an important marker for poor outcome,
and one that is ripe for cost-effective intervention if
level 1 evidence of efficacy can be shown. In a recentpreliminary analysis, we have shown that thrombus area,
as measured by a model that simulates ex vivo coronary
artery blood flow, is higher in people with SCH 7 to
10 days post non-ST elevation AMI despite dual anti-
platelet therapy (with aspirin and clopidogrel) [18]. In
multivariate analysis, serum TSH concentrations were
directly associated with thrombus area, with a strength
of association similar to other established cardiac risk
factors such as diabetes mellitus and hypertension [18].
It is currently unknown whether levothyroxine treatment
in SCH patients after an AMI can improve ventricular
function, improve endothelial function and improve blood
coagulability and rheology. Therefore, this project aims to
provide level 1 evidence to answer these important ques-
tions. This programme has two separate yet interlinked
studies: ThyrAMI 1 - an observational longitudinal study
to assess association of thyroid function at the time of
AMI with cardiovascular outcomes, and ThyrAMI 2 - a
randomised placebo-controlled interventional study of
levothyroxine in SCH patients to evaluate effect on LV




The aim of this trial is to assess what proportion of indi-
viduals with AMI have thyroid dysfunction and whether
thyroid function at the time of AMI is related to adverse
vascular outcomes.
Study design
The study is designed as a prospective longitudinal obser-
vational study of unselected patients with AMI who will
be followed for 24 months (Figure 1).
Primary objectives
The primary objective is to assess the association between
thyroid status at the time of AMI (within 24 hours of
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onary revascularisation or death due to ischaemic heart
disease) over 24 months.
Secondary objectives
The secondary objectives are as follows:
1. The proportion of individuals with thyroid dysfunction
at the time of AMI (overt hypo- and hyperthyroidism,
subclinical hypo- and hyperthyroidism, and isolated
low FT3)
2. Association between thyroid function at the time of
AMI with markers of severity of AMI (troponin, LV
function, and coronary artery disease on angiogram).
3. Relation between thyroid function at the time of AMI
with all-cause mortality over 24 months.
4. Association between thyroid function at the time
of AMI with new diagnoses of heart failure, atrial
fibrillation or stroke.
Participant population
The study population are patients post-AMI in five
different hospitals in the North East of England.
Inclusion criteria are as follows:
1. Adult males and females (aged 18 years or older).
2. Acute myocardial infarction diagnosed in the preceding
24 hours (defined as chest pain with dynamic ECG
changes or increased troponin enzymes (at least a
fourfold increase above the local laboratory reference
range).
3. Participants in other research studies will be eligible
for inclusion as this is an observational study.
Exclusion criteria are as follows:
1. Patients who are unable to provide informed consent.
2. Those with advanced malignancy (who are unlikely
to survive for more than 6 months in the opinion of
local investigator).
3. Those on medications that can affect thyroid function
such as amiodarone, lithium, carbimazole and
propylthiouracil. Patients on levothyroxine will be
included, but their results will be analysed separately.
Screening, recruitment and consent
Identification, screening and recruitment of participants
Eligible participants will be identified from acute hospitals.
All individuals that fit the study criteria will be approached
and provided with a participant information sheet for
ThyrAMI 1, and informed consent will be obtained. They
will have their thyroid function checked, and a case record
form will be completed. Patients that are otherwise eligible
to be included but have been discharged and have not hadtheir thyroid function checked will be approached via
telephone, and initial consent will be obtained prior to
requesting these tests be done on the stored serum, if
still available in the Laboratory. A screening log will be
kept at each site with a unique identifier for each partici-
pant who is approached for the study. Recruitment will
take place over a period of 12 months in all participating
centres See Figure 1.Consent procedures
All informed consent discussions will be undertaken by
experienced research staff (per delegation log) involved
in the study with an opportunity for participants to ask
any questions. Following receipt of information about
the study (that is, provision of the study invitation pack),
participants will be given reasonable time to decide whether
or not they would like to participate. Those wishing to take
part will provide written informed consent by signing and
dating the study consent form and initialling relevant sec-
tions, which will be witnessed and dated by a member of
the research team with documented, delegated responsibil-
ity to do so. Participants for ThyrAMI 1 will be informed
via the Participant Information Sheet that they may be
approached to consider participating in ThyrAMI 2 if their
thyroid blood tests are in the inclusion range.
The original signed consent form will be retained in the
Investigator Site File, with a copy in the relevant clinical
notes and a copy provided to the participant. The partici-
pant will specifically consent to their GP being informed
of their participation in the study. The right to refuse to
participate without giving reasons will be respected.
The information sheet and consent form for the study
will be available only in English. Interpreters will be ar-
ranged for all visits of participants who require them ei-
ther for verbal translation or for deaf participants wishing
to take part in the study, via local NHS arrangements.
Qualified interpreters will be used to explain the consent
form and information sheet, and great priority will be
placed on finding the most direct communication.Data analysis
The relationship between the outcomes and thyroid status
categories (euthyroid, subclinical hypothyroid, subclinical
hyperthyroid and isolated low FT3) will be examined. A
chi-squared test will be used to investigate the association
between categorical measures of thyroid status and
categorical and/or binary measures of CV outcome. In-
dependent sample t-tests will be used to investigate the as-
sociation between continuous measures of thyroid function
(TSH, FT4 and FT3) and binary measures of CV outcome.
Cox regression models will be used to explore the associ-
ation between continuous and categorical measures of CV
with survival (time to event).
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Objective
To determine whether treatment of SCH with levothyrox-
ine following AMI improves left ventricular function,
thrombus area, endothelial function, health status, quality
of life and is safe.
Study design
This study is a prospective randomised placebo-controlled
trial of levothyroxine of 12 months duration in patients
with subclinical hypothyroidism (serum TSH persistently
4.01 to 10.0 mU/l, normal FT4) starting within 21 days
following AMI. The day of AMI is the date of diagnosis or
the date of admission to hospital, whichever is later.
Primary outcome measure
The primary outcome measure will be change in LV ejec-
tion fraction as assessed by magnetic resonance imaging.
Cardiac magnetic resonance (MR) is considered the gold
standard for evaluating cardiac volumes and function [19].
Gradient echo sequences provide a naturally high level
of contrast between intracavitary blood and myocardium,
thus allowing an accurate and reproducible determination
of LV volumes, mass and calculation of stroke volume and
ejection fraction. In this context, additional information
can also be drawn from application of the more recent
cardiac MR tagging analysis, which represents a noninva-
sive highly accurate method for direct quantification of re-
gional systolic function [20]. Cardiac MR imaging will be
performed in the dedicated 3 T MRI centre at Newcastle
University.
Secondary outcome measures
Secondary outcome measures will include the following:
1. Left ventricular systolic and end diastolic volumes
and myocardial viability: Cardiac MR parameters of
both global and segmental LV function
measurements will be obtained as per standardised
protocols already in place in the Newcastle MR
centre using a steady state free precession or fast
gradient echo technique. In addition, further scans
will be obtained 15 to 20 minutes after intravenous
gadolinium-chelate administration (delayed enhancement
MRI). Regions of nonviable myocardial tissue will
be identified as areas of increased enhancement
(hyper enhancement) whereas viable tissue will
have null (black) on the acquired images.
2. Thrombus burden: The Badimon chamber is a highly
reproducible clinical ex vivo model of thrombosis
that mimics flow conditions within the coronary
circulation of man [21]. The device incorporates
two chambers with internal flow channels of different
diameters, one simulating high-shear flow of1690 ml/s and the other simulating low-shear flow.
The internal flow channels are lined with porcine
aortic tunica media - the thrombogenic substrate.
After perfusion with venous blood from the patient,
flowing at 10 mL min −1 for 5 min, aortic segments
are fixed in 10% formalin for 72 h. Total thrombus
burden is measured using validated computer-assisted
planimetry using IMAGE-PRO PLUS software (Media
Cybernetics, Inc., Bethesda, MD, USA). The results are
the mean of the analysed sections (μm2 .mm-1). The
measurements will be performed at the Clinical
Research Facility (CRF), where there are professionals
who have considerable experience using this technique
in other high vascular risk groups.
4. Thromboelastography (TEG™): This is a noninvasive
measure for evaluating efficiency and quality of
ex vivo thrombus formation. Quantitative measures
include clotting time parameters, clot strength and
clot lysis. These parameters have been validated as
highly correlated with longer term cardiac outcomes
in several conditions of risk [22,23]. TEG™ will be
measured at the CRF, RVI, Newcastle.
5. Endothelial function: Endothelial dysfunction is the
earliest stage in the atherosclerosis disease process.
In this study, endothelial function will be assessed by
measuring peripheral arterial tone using a validated
tool, EndoPAT™ [24]. Endothelial function assessment
using the EndoPAT™ has been shown to have a high
degree of correlation with coronary artery endothelial
function [25], the severity and extent of coronary
artery disease [26], and traditional cardiovascular
risk factors [27] and is useful in predicting future
cardiovascular events [28]. EndoPAT™ assessments
will be performed at the Clinical Research Facility,
RVI, Newcastle at baseline and at the end of the
study.
6. Platelet reactivity: The reactivity (inhibition) of
platelets to anti-platelet agents such as aspirin,
clopidogrel, prasugrel and ticagrelor will be quantified
by the point-of-care monitor VerifyNow™ (Accumetrics,
CA, USA). Arachidonic acid reactive units and P2Y12
reactive units will be recorded at baseline and at
the end of the study. This test will not be carried
out in individuals who take anticoagulants such as
warfarin.
7. Safety assessments: The safety of levothyroxine therapy
in post-AMI patients will be assessed at each study
visit by enquiry of symptoms by New York Heart
Assessment (NYHA) category classification, ECG
recording for rhythm disturbance and peripheral
oxygen levels by pulse oximetry (at rest).
8. QoL and depression: This will be assessed by
validated tool of measuring health status, the Short
Form 12 four week recall (SF-12™), a disease specific
Figure 2 Flow chart representing the levothyroxine post-acute
myocardial infarction in patients with subclinical hypothyroidism
interventional trial (ThyrAMI 2).
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With Heart Failure Questionnaire™, and the Centre
for Epidemiologic Studies Depression Scale (CES-D),
at baseline and at the end of the study.
Participant population
Inclusion criteria
The inclusion criteria are as follows:
1. Males and females aged between 18 to 75 yrs.
2. Serum TSH between 4.01 to 10.00 mU/L with
normal free thyroxine levels (9 to 25 pmol/L) on
two occasions (on day of admission for AMI and 7
to 10 days after AMI).
3. Acute myocardial infarction diagnosed on admission
to hospital (chest pain with dynamic ECG changes
or increase troponin enzymes (at least a fourfold
increase above the laboratory reference range).
Exclusion criteria
The exclusion criteria are as follows:
1. Patients on medications that affect thyroid function
(levothyroxine, carbimazole, propylthiouracil,
amiodarone, lithium).
2. Patients who are unable to provide written informed
consent.
3. Patients with advanced malignancy (who, in the
opinion of the investigator, are unlikely to survive
for more than 6 months).
4. Patients with sustained ventricular tachycardia
requiring treatment that occurs >24 hrs after
myocardial reperfusion/revascularisation.
5. Patients who have contra-indications to MR scanning
(cardiac pacemaker, metallic heart valves, cochlear
implants, coronary artery stents incompatible with
MR scanning, etcetera).
6. Patients who are unlikely or unwilling, in the opinion
of the investigator, to attend for study-specific visits.
7. Participants whose serum TSH is >10.0 or <4.0 on
either occasion.
8. Patients who are already participating in another
interventional study.
Screening, recruitment and consent
Identification, screening and recruitment of participants
Eligible participants will be identified from the cardiology
units of acute hospitals in the North East of England
(Gateshead, Newcastle, Sunderland, South Tyneside and
North Tyneside Hospitals). All individuals who fit the
study inclusion and exclusion criteria will have their
thyroid function checked, after informed consent is ob-
tained, within 24 hours of diagnosis of AMI. Of these
patients, those that have TSH and FT4 levels within theinclusion range will be provided with a participant in-
formation sheet for ThyrAMI 2. Furthermore, these in-
dividuals will be invited to have a repeat thyroid blood
test 7 to 10 days after the day of AMI. The day of AMI
is the date of diagnosis or the date of admission to the
hospital, whichever is later. Those individuals who have
TSH and FT4 levels within the inclusion range on the
second occasion will be asked to participate in the study
and sign the consent form (Figure 1). Those who do not
attend for their second visit blood test will be contacted to
enquire whether they are still interested in participating.
Once a participant has had thyroid blood results that
are within the desired range for inclusion in the study
on two occasions and has consented to participate in the
study, the study team will arrange a convenient date and
time for the baseline tests and randomisation to the treat-
ment groups (see Figure 2). The dates for the baseline
tests will be within 21 days of the patients’AMI dates.
A screening and recruitment log will be held securely at
the Investigator sites. The screening log will document
anonymised details of patients invited to participate in the
study. A participant recruitment/ID log will record those
who consented to participate in the trial.
Consent procedures
All informed consent discussions will be undertaken by
experienced research staff (per delegation log) involved
in the study with an opportunity for participants to ask
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study (that is, provision of the study invitation pack), par-
ticipants will be given reasonable time to decide whether
or not they would like to participate. Those wishing to
take part will provide written informed consent by signing
and dating the study consent form and initialling the
relevant sections, which will be witnessed and dated by
a member of the research team with documented, dele-
gated responsibility to do so. Written informed consent
will always be obtained prior to any study specific pro-
cedures or investigations, including those necessary to
confirm eligibility or arranging any study-specific visits.
The original signed consent form will be retained in the
Investigator Site File, with a copy in the relevant clinical
notes and a copy provided to the participant. The partici-
pant will specifically consent to their GP being informed
of their participation in the study. The right to refuse to
participate without giving reasons will be respected.
The information sheet and consent form for the study
will be available only in English. Interpreters will be ar-
ranged for all visits of participants who require them either
for verbal translation or for deaf participants wishing to
take part in the study, via local NHS arrangements.
Qualified interpreters will be used to explain the con-
sent form and information sheet, and great priority will
be placed on finding the most direct communication.
Participants who lack capacity to consent for themselves
will be excluded from the study.
Intervention
Levothyroxine (LT4) will be used to achieve a target
TSH level of 0.4 to 2.5 mU/L.
Control
A placebo will serve as the control.
Randomisation
Participants will be randomised using a computerised ran-
domisation algorithm, stratified by type of MI (NSTEMI
versus STEMI), in a 1:1 ratio to levothyroxine therapy or
placebo (as container or bottle numbers), starting within
21 (+/− 7) days of the AMI (date of diagnosis or the date
of admission to hospital, whichever is later). In addition,
investigators will be unaware of allocation and will be
blinded to treatment groupings. Randomisation will be
administered centrally via Newcastle Clinical Trials Unit
using a secure password-protected web-based system.
Blinding
Assignment to either the LT4 or placebo arm will be
blinded to the participant as well as study team (double-
blind). Code break envelopes will be available at the
pharmacy at each site.Study medication will be prescribed by the study team
at each site using a trial-specific prescription (documenting
the required IMP pack number), and dispensed according
to local pharmacy practice. Independent study physicians,
who will be unblinded, will adjust study drug dose as per
protocol. The relevant pharmacy will hold a corresponding
list allowing pharmacy staff to correlate IMP pack number
with relevant packaged IMP dose for any particular IMP
bottle, thus maintaining the double-blind.
At the final visit, the integrity of the blind will be
assessed by asking the participants: “It is important for the
interpretation of the results of the study that we ask
you the following: Do you think you were taking LT4 or
placebo? Why do you think this?”Study medication
The LT4 medication (IMP) will be used within their li-
censed indications in this study [29,30]. Nonetheless,
since LT4 is being compared to a placebo, additional in-
formation is being gathered on the safety and efficacy, and
manufacture will involve de-blistering/over-encapsulation;
the placebo will be treated as an Investigational Medicinal
Product (IMP) for the purpose of this study, and will be
labelled and handled accordingly.
The study drug will be sourced, assembled and pack-
aged by Newcastle Specials (Pharmacy Production Unit)
at The Newcastle upon Tyne Hospitals NHS Foundation
Trust, MIA (IMP) 17136. The LT4 to be used in this
study will be generic Levothyroxine 25 mcg and 50 mcg
tablets (Amdipharm Mercury Ltd). This will be purchased
in blister packs.
The double-blind will be achieved by de-blistering and
over-encapsulation, using a capsule filler of Lactose BP.
For doses that are multiples of 50 mcg, we will over-
encapsulate Levothyroxine 50 mcg tablets; for the remaining
25 mcg, 75 mcg and 125 mcg dose increments, we will
over-encapsulate Levothyroxine 25 mcg tablets. This
ensures the capsule size is kept as small as possible for
swallowing purposes (DB capsules Size A, colour: Swedish or-
ange; manufacturer: Capsugel). Capsules will be re-packaged
into an appropriate bottle container (polypropylene)
and labelled.
As it is not feasible to predict in advance exactly how
much IMP must be packaged per study dose, predictions
will be based on known current doses as per routine
clinical practice; production run(s) will generate surplus
stock per IMP dose. The LT4 medication will have a
shelf-life maximum of 24 months (less any reduction in
expiry due to the shortest expiry date of blister packs
purchased). The IMP should NOT be stored above 25 °C
and must be stored in the original container to protect it
from light and moisture, as per the clinical trial label. A
temperature log will be maintained as per local pharmacy
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teed until the IMP arrives in patient possession.
The side effects of LT4 (25 mcg and 50 mcg) are well
known and documented [29,30]. The total daily dose
provided to each participant will be between 25 mcg and
150 mcg.
Administration of the study drug
Participants will be randomised to either LT4 or placebo
to be taken orally once daily. This will be discussed at
the time of consent and will be clear in the patient infor-
mation sheet. Initial starting dose of LT4 will always be
25 mcg daily. To achieve the desired target TSH levels
in the LT4-treated group (target TSH levels 0.4 to
2.5 mU/L), participants will have their TSH levels checked
every 4 weeks and concomitant dose of their LT4 altered
by 25 mcg daily, if required. The IMP will be provided as
5 week supplies of LT4 or matching placebo (dispensed
separately at each visit), packaged into appropriate individ-
ual polypropylene bottles. The label on the bottle will not
indicate details of the arm of the study to which the partici-
pant has been randomised. The label will instead contain a
pack number, which will be the link to the relevant dose.
Study medication will be prescribed by the PI or co-
investigator at each site using a trial-specific prescription
(documenting the required IMP pack number), and dis-
pensed according to local pharmacy practice. Independent
study physicians who will be unblinded will adjust study
drug dose as per protocol. The relevant pharmacy will
hold a corresponding list allowing the pharmacy staff to
correlate the IMP pack number with relevant packaged
IMP dose for any particular IMP bottle, thus maintain-
ing the double-blind.
Participants will be informed of potential adverse reac-
tions and advised to contact the relevant study team if re-
quired. A study-specific participant contact card will also
be provided.
Once randomised, the participant will begin their study
medication on Day 0.
At 4, 8, 12 and 24 weeks (+/− 7 days), serum TSH levels
will be checked and LT4 doses adjusted as follows (the
next bottle of IMP should be started at week 4, 8, 12,
24 +/− 7 days, respectively):
LT4 group:
TSH 0.4 to 2.5 mU/L: Continue LT4 at current dose once
daily
TSH > 2.5 mU/L: LT4 increased by 25 mcg daily
TSH < 0.4 mU/L: LT4 reduced by 25 mcg, or if already
on 25 mcg daily (the lowest possible dose), then
recheck TFTs in 4 weeks. If TSH is ≥0.4 mU/L then
continue on current dose. Otherwise, if TSH continues
to be <0.4 mU/L on the repeat blood test, then the
participant will be withdrawn from the study.Placebo group:
Individuals in this group will have a fresh bottle of IMP
starting at 4, 8, 12, 24 +/− 7 days after blood tests to
maintain the double blind.
LT4 treatment based on the above regimen will con-
tinue for a total of approximately 52 weeks at which
point the final set of study specific assessments will be
made (with a further follow-up phone call at approxi-
mately 53 weeks). If a participant in the placebo arm has
a TSH >10 mU/L then their TFTs will be rechecked in
4 weeks. If, the TSH is ≤10 mU/L on the repeat test then
the participant will continue with the study and, if, the
TSH continues to be >10 mU/L then the participant will
be withdrawn from the study. At the final visit, partici-
pants on each arm of the study will stop their IMP and
will be referred back to their GP to have their thyroid
function checked in 6 to 12 weeks. The GP and the pa-
tient will be encouraged to discuss whether there is a
need to commence LT4 therapy in these individuals based
on the clinical situation. The GP letter (sent once the
participant is randomised) and the GP follow-up letter
(sent after each participant completes their IMP) outlines
the suggestion to recheck TSH levels at 6to 12 weeks for
each participant once they have completed their IMP.
At the end of each visit, participants will be asked to
return any surplus study drug in the original packaging
to the study team, who will verify and document compli-
ance. All unused study medication and packaging will be
sent to the local pharmacy for documentation and destruc-
tion as per local policy (following appropriate reconciliation
by the Trial Manager). Documentation of prescribing, dis-
pensing and return of study medication shall be maintained
for study records.
Data collection and outcome assessments
The schedule of events for ThyrAMI 2 is shown below
in Table 1.
Data handling and record keeping
Medical information obtained at each visit will be recorded
in the subject’s medical notes or other source docu-
mentation in real time. Data will be collected and en-
tered into a secure, validated clinical data management
system (MACRO), by an authorised member of the re-
search study team. The data management system will
be 21 CRF Part 11 compliant. Data for each visit will be
entered by relevant local staff at each site. The clinical
data management system will be web based; allowing
access to authorised staff via password protection. Data
will be handled, computerised and stored in accordance
with the Data Protection Act 1998. No participant iden-
tifiable data will leave the study site (CRFs will identify
Table 1 Schedule of events for ThyrAMI 2
Pre-screening Baseline Randomisation follow-up





























Eligibility criteria checked X













Safety checks (ECG, pulse
oximetry and NYHA
assessment
X X X X X X















at visits 2 to 5 only)
X X X X
Study medication
compliance checks
X X X X X
Concomitant medication X X X X X
Adverse events X X X X X X
Serious adverse events X X X X X X
X* 20 ml blood: TSH, FT4, FT3, TPO antibodies, Total cholesterol, HDL, Triglycerides, serum BNP, endothelial markers (10 ml gel/gold tube and 10 ml EDTA/purple tube).
X** 5 ml blood: TSH, FT4, FT3 only (gel/gold tube).
Height ****: To be measured at baseline visit only (or could be self-reported if apparatus not available; for example at participant’s home).
ǂ After full discussion and answering any questions.
List of Abbreviations:
BP, blood pressure; BTF, British Thyroid Foundation; CES-D, Centre for Epidemiologic Studies Depression Scale; ECG, electrocardiogram; LT4, levothyroxine;
MLWHFQ, Minnesota Living With Heart Failure Questionnaire; MRI, magnetic resonance imaging; NYHA, New York Heart Association; PIS, patient information sheet
(s); SF12, short-form health survey; TEG, thromboelastography.
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number only). Strict confidentiality will be ensured while
dealing with patient-sensitive data in accordance with
the Caldicott Guardian’s recommendations (applications
will be made to the relevant Caldicott Guardian for use of
NHS patient data).
All study data will be held in strict confidence by
the investigators/research team. Data and documentswill be stored in locked cupboards. A confidential list
of trial identifiers and corresponding patient identi-
fying details will be held at site in a locked cupboard
by the Principal Investigator. The quality and reten-
tion of study data will be the responsibility of the
CI. All study data will be retained in accordance with
the latest Directive on GCP (2005/28/EC) and local
policy.
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Clinical Research Network
This study will apply for adoption to the NIHR CRN
Portfolio. Accrual data will be submitted on a monthly
basis, by a delegated member of staff at the Newcastle
Clinical Trials Unit, in accordance with NIHR CRN
guidelines.
Statistical considerations for ThyrAMI 2
Sample size
Left ventricular ejection fraction (LVEF) is considered to
be the strongest predictor for adverse outcomes after an
acute myocardial infarction (AMI). Previous randomised
trials in patients with acute myocardial infarction that
showed reduced mortality and morbidity demonstrated
concurrent absolute differences in LVEF of 3 percentage
points or more [31,32]. Therefore, we considered this to
be a feasible and clinically important difference. The sam-
ple size calculation is based on the assumption that impact
of the intervention will be assessed using analysis of
covariance and uses the method described by Frison and
Pocock (1992) as implemented in the sampsi procedure in
Stata 13 [33].
The ThyrAMI 2 study is designed with 90% power to
detect an overall difference of 3% in LVEF between the
two groups (3% improvement in the placebo group and
6% in the LT4 group) 12 months after AMI, at a two-sided
significance level of 5%. The SD of the effect measure
is estimated to be a broad 6% [34]. Using ANCOVA
(differences in change in EF from baseline between pla-
cebo and LT4 taking into account variability in the base-
line with correlation between baseline and follow-up of
0.75), we calculate that 47 patients would need to be en-
rolled in each group, allowing for a 10% drop-out.
Sampling and recruitment
A feasibility analysis showed that approximately 150
patients per month are admitted to two coronary care
units in the northeast. Based on our previous study, we
anticipate that 10 to 17% of these patients will have
SCH [18]. If 50% of these patients will consent to par-
ticipate in the trial, we will complete recruitment in
12 months at 8 participants per month.
Statistical analysis
The primary analysis will be an intention to treat ana-
lysis of change in LVEF before and after levothyroxine
therapy. The dependent variable will be LVEF at follow-up;
baseline LVEF will be included as a covariate. Residual er-
rors will be assumed to have a normal error distribution.
The difference between patients randomised to LT4 and
placebo will be fit as a fixed effect. Model assumptions
will be checked, and if necessary, transformations of
the dependent variable will be considered. A secondaryper protocol analysis of change in LVEF before and after
levothyroxine therapy will also be performed. Both primary
and secondary outcomes will be measured at baseline
(prior to start of the interventional medication as well
as at 52 weeks (end of study). Change in secondary out-
comes between the LT4 and placebo groups will be com-
pared using analysis of covariance. Variables that are not




Compliance with study medication (IMP) will be assessed
and documented by the research team by checking and
recording the number of returned capsules at each visit.
This allows any issues to be addressed immediately with
the participant. Compliance will be classed as good if be-
tween 80 to 100%. The local pharmacy will also document
all unused study medication/packaging prior to appropri-
ate reconciliation by the Trial Manager.
Withdrawal of participants
Participants have the right to withdraw from the study at
any time for any reason without giving a reason. The in-
vestigator also has the right to withdraw patients from the
study drug in the event of inter-current illness, adverse
events, serious adverse events, suspected unexpected ser-
ious adverse reactions, protocol violations, administrative
reasons or other reasons.
Should a participant decide to withdraw from the study,
their wishes will be respected. These participants will be
asked to complete a “confirmation of withdrawal” form to
document their decision. However, for participants that
withdraw due to reasons other than related to tolerance of
MR scanning, they would be offered the chance to have
the primary outcome assessment (cardiac MR imaging)
performed at the time of withdrawal.
Participants who have serum TSH <0.4 or >10.0 mU/L
on two separate occasions at least 4 weeks apart whilst
on study drug will be withdrawn from the study due to
safety reasons. For study participants who withdraw from the
study, a replacement eligible participant will be recruited, if
the study is still recruiting.
Monitoring, quality control and assurance
The study will be managed by the Chief Investigator,
Research Nurse and through NCTU. The Trial Management
Group (TMG) will include the Chief Investigator, Trial
Statistician, Trial Manager and Research Nurse.
The Principal Investigators will be responsible for con-
ducting the study day-to-day at the site.
The Chief Investigator, Research Nurse and NCTU
will provide day-to-day support for the sites and provide
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toring visits.
Quality control will be maintained through adherence
to Newcastle Biomedicine Clinical Research Platforms
SOPs, study protocol, the principles of GCP, research
governance and clinical trial regulations.
An independent Data Monitoring and Ethics Committee
(DMEC) comprising independent team members: chair,
local expert and statistician will be convened to undertake
independent review. The purpose of this committee will be
primarily to monitor safety endpoints. The committee will
meet at least twice a year after recruitment commences to
identify any safety issues.
A Trial Steering Committee (TSC) chaired by an inde-
pendent lay expert will be established to provide overall
supervision of the trial. The TSC will meet at least yearly.
At the request of the TSC, interim meetings, in person or
by teleconference, will be organised. Any major trial issues
may need to be dealt with between meetings, by phone or
by email.
Monitoring of study conduct and data collected will
be performed by a combination of central review and
site monitoring visits to ensure the study is conducted
in accordance with GCP and with adherence to the
Trial Monitoring Plan, which will be agreed on with the
Sponsor. Study site monitoring will be risk-based and
will be undertaken by NCTU. The main areas of focus
will include consent, serious adverse events, essential
documents in study files and drug accountability and
management.
Site monitoring plan is likely to include the following:
1. All original consent forms will be reviewed. The
presence of a copy in the participant hospital notes
will be confirmed for a percentage of participants.
2. All original consent forms will be compared against
the study participant identification list.
3. All reported serious adverse events will be verified
against treatment notes/medical records.
4. The presence of essential documents in the investigator
site file and study files will be checked.
5. Source data verification for a selection of data/
participants entered into the study (for example,
primary endpoint data and eligibility data).
6. Drug accountability and management will be checked.
7. Central monitoring will include:
8. All applications for study authorisations and submissions
of progress/safety reports will be reviewed for accuracy
and completeness, prior to submission.
9. All documentation essential for study initiation will
be reviewed prior to site authorisation.
All monitoring findings will be reported and followed
up in a timely manner.The study may be subject to inspection and audit by
designated staff from the Gateshead Health NHS Foun-
dation Trust under their remit as Sponsor, and other regu-
latory bodies to ensure adherence to GCP. The investigator
(s)/institutions will permit trial-related monitoring, audits,
REC review and regulatory inspection(s), providing direct
access to source data/documents. The study’s Patient
Information Sheets and consent forms will make it clear
that this level of access to records is required.
Pharmacovigilance
The safety of LT4 in this study will be evaluated by exam-
ining the occurrences of all adverse events, adverse drug
reactions, unexpected adverse reactions, serious ad-
verse reactions or suspected unexpected serious ad-
verse reactions as defined by the Medicines for Human
Use (Clinical Trials) Regulations [35]. The relationship and
expectedness of the adverse event or reaction (causality)
will be assessed by the site investigator and relayed to the
chief investigator who, on behalf of the sponsor (Gateshead
Health NHS Foundation Trust), will notify the regulatory
bodies, the Medicines and the Healthcare Products
Regulatory Agency (MHRA) and the research ethics com-
mittee (REC), within 7 days for fatal and life-threatening
events and 15 days for non-life-threatening events. All
study investigators will be notified.
Most adverse events and adverse drug reactions that
occur in this study, whether they are serious or not, will
be expected treatment-related toxicities due to the drugs
used in this study. For a full list of expected undesirable
effects of Levothyroxine, please refer to the relevant Sum-
maries of Product Characteristics [29,30].
We do not anticipate adverse effects of LT4. Neverthe-
less, safety of participants is of paramount importance,
and therefore, LT4 dose will be commenced at a small
dose (25 mcg daily) and the dose increased every 4 weeks
by 25 mcg daily until the serum TSH is within the required
range. Safety measures (ECG, symptoms of heart failure,
and pulse oximetry) will be assessed at visits 2 to 6. If
severe hypothyroidism develops (TSH >10 mU/L with
low FT4 levels), then symptoms including fatigue, weight
gain and poor memory may develop. For such individuals,
we will recheck TFT in 7 days. If serum TSH remains
above 10 mU/L, then such patients will be withdrawn
from the study. In addition, we will assess the health of
participants via a health status questionnaire. Participants
will also be provided with a helpline number in case they
experience any problems.
For purposes of this protocol:
1. All non-serious adverse events will be recorded at
the follow-up visits 2 to 6.
2. Any serious adverse events will be recorded throughout
the duration of the trial until week 52 (+/− 3 days).
Jabbar et al. Trials  (2015) 16:115 Page 11 of 133. Serious adverse events exclude any pre-planned
hospitalisations (for example, elective surgery) not
associated with clinical deterioration.
4. Serious adverse events exclude routine treatment
or monitoring of the studied indication (that is,
hypothyroidism), not associated with any
deterioration in condition.
5. Serious adverse events exclude elective or scheduled
treatment for pre-existing conditions that did not
worsen during the study.
Confidentiality
Personal data will be regarded as strictly confidential. To
preserve anonymity, any data leaving the site will identify
participants by their initials, date of birth and a unique pa-
tient number only. The study will comply with the Data
Protection Act, 1998, and Caldicott guidelines. All study
records and Investigator Site File(s) will be kept at site in a
locked filing cabinet with restricted access. The Trial
Master File will be held at Newcastle Clinical Trials
Unit in a locked filing cabinet with restricted access.
All laboratory samples (sent for analysis to the Depart-
ment of Clinical Biochemistry, Gateshead Health NHS
Foundation Trust) will be labelled with a unique patient
number, initials and date of birth (linked in anonymised
form), with the centre number and visit number and
date/time of sample.
Ethics and regulatory issues
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical
Assembly, Helsinki 1964 and later revisions.
Favourable ethical opinion from an appropriate Research
Ethics Committee (NRES Committee North East -
Sunderland, 14/NE/0151) and Clinical Trial Authorisation
from the Medicines and Healthcare Product Regulatory
Agency has already been obtained. The approving R&D
committees include the following: The Newcastle upon
Tyne Hospitals NHS Foundation Trust, Gateshead Health
NHS Foundation Trust, City Hospitals Sunderland NHS
Foundation Trust and Northumbria Healthcare NHS
Foundation Trust. All local approvals will be obtained
before recruitment commences at each site. The Study
Coordination Centre will require a written copy of local
approval documentation before initiating each centre
and accepting participants into the study.
Discussion
Acute myocardial infarction (AMI) and its related
complications represent a major public health problem.
Despite improvements in reperfusion therapy, the 2020
World Health Organisation projections view the high
incidence of post-ischaemic heart failure as the mostimportant cause of morbidity and mortality [36]. Limita-
tion of infarct size extent and recovery of dysfunctional
contractile segments are the key elements for preventing
post-ischaemic left ventricular remodelling. Therefore,
despite research into new reperfusion strategies, a new
perspective involves studying mechanisms by which
myocytes can self-protect at times of stress, which can
prevent irreversible cell death. In this regard, thyroid
hormones are increasingly being recognised as significant
players in the pathogenesis and the recovery and repair
period of AMI [36,37].
Even mild hypothyroidism, known as subclinical
hypothyroidism, is associated with worse cardiovascular
outcomes. The prevalence of SCH is higher than that of
type 2 diabetes mellitus (5-10%) and is more common in
women and the elderly [4,38]. Small intervention trials of
levothyroxine in SCH have shown improvement in left
ventricular function, vascular endothelial function and
atherogenic lipid particles [8]. The Cardiovascular Health
Study showed that SCH participants who were treated
with levothyroxine had a 72% reduction in heart failure
events [14]. Thus, even mild hypothyroidism following
AMI could be an important marker for poor outcome.
No clinical trial has assessed outcomes of SCH in myocar-
dial infarction and whether treating this state can improve
outcomes by increasing left ventricular function, reducing
thrombogenesis, improving endothelial function and
quality of life. Therefore ThyrAMI 1 and ThyrAMI 2 will
be the first trials investigating SCH in myocardial in-
farction to give a better insight into whether thyroid hor-
mone levels are a key target for improving cardiovascular
outcomes.
Trial status
The study received National Health Service (NHS) ethics
approval on 28 May 2014 (NRES Committee North East -
Sunderland), MHRA approval on 30 October 2014, and
NHS Trust R&D governance approvals are awaited. Re-
cruitment will commence on 22 December 2014 and
proceed until May 2016. Results will be submitted for
publication in 2017.
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